Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENT: Talazoparib With or Without Enzalutamide in mCRPC With HRR Mutations
NCT06844383Phase 2Recruiting
- Sponsor
- Prostate Cancer Clinical Trials Consortium
- Start
- May 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of talazoparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Prostate Cancer Clinical Trials Consortium. Primary endpoint: Radiographic Progression-Free Survival at 42 months. Started May 2026; status: recruiting.
02
Drugs
talazoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06844383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844383.